Misinformation on biosimilars is costing the U.S. billions - STAT

Misinformation on biosimilars is costing the U.S. billions - STAT

Combatting misinformation on biosimilars and preparing the market for them can save the U.S. billions

By HILLEL P. COHEN AND DOROTHY MCCABE

ADOBE

Biosimilars haven't been embraced by patients, physicians, and payers due partly to misinformation — some of it coming from the pharmaceutical industry.

READ MORE